🇺🇸 FDA

Intelligence · INN Directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed
4,797
Companies
1,769
Pipeline programs
20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Showing page 106 of 200 · A–Z by INN

  1. lantuparvovec

    NMPA: clinical trials

  2. lapatinib

    TYKERB Novartis Pharmaceuticals

    EMA: approved · TGA: approved

    L01EH01

  3. lapatinib ditosylate

    LAPATINIB DITOSYLATE Teva Pharma GmbH

    ORAL FDA: approved

  4. lapyrium chloride

    VIRAC REX

    TOPICAL FDA: approved

  5. laquinimod

    NERVENTRA Teva Pharma GmbH

    EMA: refused

    N07

  6. laronidase

    ALDURAZYME BioMarin Pharmaceutical Australia Pty Ltd

    FDA: approved · EMA: approved

    A16AB05

  7. laropiprant

    TREVACLYN

    EMA: withdrawn

    C10AD52

  8. larotinib

    NMPA: clinical trials

  9. larotrectinib

    VITRAKVI Bayer Australia Ltd

    EMA: approved · TGA: approved

    L01XE53

  10. larotrectinib sulfate

    VITRAKVI

    ORAL FDA: approved

  11. lasmiditan

    RAYVOW

    FDA: approved · EMA: approved

    N02CC08

  12. lasmiditan succinate

    REYVOW

    ORAL FDA: approved

  13. lasofoxifene

    FABLYN

    EMA: unknown

    G03

  14. latanoprost

    APO-LATANOPROST Alphapharm Pty Ltd

    OPHTHALMIC FDA: approved · EMA: approved · TGA: approved

    S01EE01

  15. latanoprost + timolol

    APO-LATANOPROST/TIMOLOL 0.05/5 Alphapharm Pty Ltd

    TGA: approved

  16. latanoprost / netarsudil

    ROCLANDA

    EMA: approved

    S01EE

  17. latanoprostene bunod

    LATANOPROSTENE BUNOD

    OPHTHALMIC FDA: approved

  18. lavender spike oil

    NULL

    TGA: approved

  19. lazertinib

    LAZCLUZE

    EMA: approved

    L01EB09

  20. lazertinib mesilate hydrate

    LAZCLUZE

    PMDA: approved

  21. lazertinib mesylate

    LAZCLUZE

    ORAL FDA: approved

  22. lcar-

    NMPA: clinical trials

  23. lebrikizumab

    EBGLYSS S.A.

    EMA: approved · PMDA: approved

    D11AH10

  24. lebrikizumab-lbkz

    EBGLYSS

    INJECTION FDA: approved

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles — INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page — it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.

Data attribution and licensing: Data sources